Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 20;23(2):101-110.
doi: 10.3779/j.issn.1009-3419.2020.02.05.

[Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer]

[Article in Chinese]
Hanfei Guo  1 , Rilan Bai  1 , Jiuwei Cui  1
Affiliations
Review

[Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer]

[Article in Chinese]
Hanfei Guo et al. Zhongguo Fei Ai Za Zhi. .

Abstract
in English, Chinese

Immune checkpoint inhibitors (ICIs) therapy is the most commonly used immunotherapy regimen at present. It has been approved for clinical treatment of melanoma, kidney cancer, head and neck cancer, bladder cancer and other tumors. It has made a breakthrough in the treatment of lung cancer and become a new pillar of comprehensive treatment of lung cancer. However, ICIs alone is less effective in non-selective patients, and combination therapy has become a hot topic of exploration. This article focuses on the development of combined immune checkpoint inhibitors and describes how immunotherapy can be used to treat early stage cancer.

【中文题目：肺癌免疫检查点抑制剂的联合治疗研究进展】 【中文摘要：检查点抑制剂（immune checkpoint inhibitors, ICIs）治疗是目前最常用的免疫治疗方案，已被批准用于黑色素瘤、肾癌、头颈癌、膀胱癌等多种肿瘤的临床治疗，在肺癌治疗中更是取得突破性进展，成为肺癌综合治疗的新支柱。但由于肿瘤的异质性及肿瘤微环境的复杂性，ICIs单药在非选择患者中有效率偏低。手术、化疗、放疗、靶向治疗等治疗手段可与免疫治疗产生协同作用，联合疗法成为目前探索的热点。本文着重于免疫检查点抑制剂联合治疗策略的研究进展，并描述了免疫疗法如何被用于早期癌症的治疗。】 【中文关键词：肺肿瘤；免疫检查点抑制剂；联合治疗】.

Keywords: Combination therapy; Immune checkpoint inhibitors; Lung neoplasms.

PubMed Disclaimer

References

    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi: 10.1038/nrc3239. - DOI - PMC - PubMed
    1. Haanen JB, Robert C. Immune Checkpoint Inhibitors. Prog Tumor Res. 2015;42:55–66. doi: 10.1159/000437178. - DOI - PubMed
    1. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074. doi: 10.1158/1078-0432. - DOI - PMC - PubMed
    1. Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer. 2016;16(2):121–126. doi: 10.1038/nrc.2016.2. - DOI - PMC - PubMed
    1. Galluzzi L, Buque A, Kepp O, et al. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97–111. doi: 10.1038/nri.2016.107. - DOI - PubMed

MeSH terms

Substances